ArticleClinical cancer research : an official journal of the American Association for Cancer Research2008
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.Expert opinion on drug discovery · 2025Review
- The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.Frontiers in oncology · 2023Article
- Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome.Pharmaceutics · 2022Review
- Therapeutic targeting of gastrointestinal cancer stem cells.Regenerative medicine · 2019Review
- Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.Blood advances · 2018Article
- Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.Nature reviews. Gastroenterology & hepatology · 2018Review
- Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells.Oncotarget · 2017Article
- Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.Oncotarget · 2017Article
- Targeting telomerase with radiolabeled inhibitors.European journal of medicinal chemistry · 2017Article
- Emerging therapeutic targets in esophageal adenocarcinoma.Oncotarget · 2016Review
- Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer.Pharmacogenomics and personalized medicine · 2015Review
- Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis.Nature communications · 2014Article
- Article
- Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells.PloS one · 2014Article
- Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target.Translational research : the journal of laboratory and clinical medicine · 2013Review
- Is telomerase a viable target in cancer?Mutation research · 2012Review
- Article
- Targeting telomerase-expressing cancer cells.Journal of cellular and molecular medicine · 2011Review
- Immunosenescence and rheumatoid arthritis: does telomere shortening predict impending disease?Autoimmunity reviews · 2011Review
- Telomeres, lifestyle, cancer, and aging.Current opinion in clinical nutrition and metabolic care · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 1 country.
Funding
Abstract
purposeThe aims of this study were to investigate telomere function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of telomerase inhibition in cancer cells in vitro and in vivo. EXPERIMENTAL
designEpithelial cells were purified from surgically resected esophagi. Telomerase activity was measured by modified telomeric repeat amplification protocol and telomere length was determined by real-time PCR assay. To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific telomerase inhibitor (GRN163L) and live cell number was determined weekly. Apoptosis was evaluated by Annexin labeling and senescence by beta-galactosidase staining. For in vivo studies, severe combined immunodeficient mice were s.c. inoculated with adenocarcinoma cells and following appearance of palpable tumors, injected i.p. with saline or GRN163L.
resultsTelomerase activity was significantly elevated whereas telomeres were shorter in BEAC cells relative to normal esophageal epithelial cells. The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis. GRN163L-induced cell death could also be expedited by addition of the chemotherapeutic agents doxorubicin and ritonavir. Finally, the treatment with GRN163L led to a significant reduction in tumor volume in a subcutaneous tumor model.
conclusionsWe show that telomerase activity is significantly elevated whereas telomeres are shorter in BEAC and suppression of telomerase inhibits proliferation of adenocarcinoma cells both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.